Skip to Content

Research & Funding

Past CIP InitiativesRSS

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PAR-14-013: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21) - Reissued

    • Release Date: March 05, 2014
    • Application Receipt Date: June 30, 2014; October 10, 2014; February 9, 2015, June 9, 2015; October 9, 2015; February 9, 2015; June 9, 2016; October 11, 2016; February 9, 2017, by 5:00 PM local time of applicant organization.
    • Expiration Date: February 10, 2017
    • Contacts: Imaging trials:
      Lori A. Henderson, Ph.D., NCI, Phone: 240-276-5930, (hendersonlori@mail.gov)
      Frank I. Lin, M.D., NCI, Phone: 240-276-5932, (frank.lin2@nih.gov)
      Image-Guided Intervention [IGI] trials:
      Keyvan Farahani, Ph.D., NCI, Phone: 240-276-5921, (farahank@mail.nih.gov)
      Radiation Therapy related trials:
      Bhadrasain Vikram, M.D., NCI, Phone: 240-276-5690, (vikramb@mail.nih.gov)

    This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

  • PAR-13-185: Image-guided Drug Delivery in Cancer (R01)

    • Release Date: May 14, 2013
    • Application Receipt Date: June 19, 2013; November 19, 2013; June 19, 2014; November 19, 2014; June 19, 2015; November 19, 2015
    • Expiration Date: November 20, 2015
    • Contacts:

      Contact: Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 240-276-5921

      Please see the FOA for a complete list of contacts.

    This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

  • PAR-13-169: Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)

    • Release Date: May 14, 2013
    • Application Receipt Date: Standard dates apply: see http://grants.nih.gov/grants/funding/submissionschedule.htm
    • Expiration Date: May 8, 2016
    • Contacts:

      Houston Baker, Ph.D.; Phone: 240-276-5908; Email: bakerhou@mail.nih.gov

      Please see the FOA for a complete list of contacts.

    This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either preclinical or clinical in vivo imaging systems and/or methods that are designed to solve a targeted cancer problem. The proposed imaging system/methods may include single or multi-modality in vivo imaging and spectroscopy systems, image-guided and drug delivery systems, image analysis, and related research resources. This FOA may also include, as a secondary goal, support for other laboratory imaging or reference methods as required to validate the performance of the proposed in vivo imaging system and/or methods. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following examples, among others: (a) current commercially supported imaging systems/methods, (b) next-generation imaging systems/methods, (c) quality assurance and quality control methods, (d) validation and correlation studies, (e) quantitative imaging methods, and (f) related research resources. Because appropriate applications must be translational in scope, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. The partnerships on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their proposed imaging system/methods to solve a targeted cancer problem. This FOA will support clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods. This FOA will not support commercial production, or basic research projects that do not emphasize translational development and optimization of the methods for a targeted cancer problem.